Vir Biotechnology Third Quarter 2022 Earnings: Beats Expectations

Vir Biotechnology (NASDAQ:VIR) Third Quarter 2022 Results

Key Financial Results

• Revenue: US$374.6m (up 262% from 3Q 2021).
• Net income: US$175.3m (up 59% from 3Q 2021).
• Profit margin: 47%.
• EPS: US$1.32 (up from US$0.84 in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vir Biotechnology Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 115%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is expected to decline by 26% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 15%.

Performance of the American Biotechs industry.

The company's shares are up 13% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Vir Biotechnology you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.